스페인 - 스페인어 - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios normon s.a. - fentanilo - parche transdÉrmico - 50 microgramos/h - fentanilo 50 microgramos/h - fentanilo

스페인 - 스페인어 - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sandoz farmaceutica s.a. - fentanilo - parche transdÉrmico - 50 microgramos/h - fentanilo 50 microgramos/h - fentanilo

스페인 - 스페인어 - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

kern pharma s.l. - fentanilo - parche transdÉrmico - 50 microgramos/h - fentanilo 50 microgramos/h - fentanilo

스페인 - 스페인어 - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

baxter, s.l. - factor ix - excipientes: cloruro de sodio,citrato de sodio (e-331) - vitamina k y otros hemostÁticos - factores de la coagulación sanguínea - factor ix de la coagulacion

유럽 연합 - 스페인어 - EMA (European Medicines Agency)

janssen-cilag international nv - paliperidona - schizophrenia; psychotic disorders - psicolépticos - invega está indicado para el tratamiento de la esquizofrenia en adultos y en adolescentes de 15 años en adelante. comercial invega está indicado para el tratamiento del trastorno esquizoafectivo en adultos.

유럽 연합 - 스페인어 - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - anakinra - arthritis, rheumatoid; covid-19 virus infection - inmunosupresores - la artritis reumatoide (ar)kineret está indicado en adultos para el tratamiento de los signos y síntomas de la ar en combinación con metotrexato, con una respuesta inadecuada a metotrexato solo. covid-19kineret is indicated for the treatment of coronavirus disease 2019 (covid-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (supar) ≥ 6 ng/ml. periodic fever syndromeskineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:cryopyrin-associated periodic syndromes (caps)kineret is indicated for the treatment of caps, including:neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca)muckle-wells syndrome (mws)familial cold autoinflammatory syndrome (fcas)familial mediterranean fever (fmf)kineret is indicated for the treatment of familial mediterranean fever (fmf). kineret debe administrarse en combinación con colchicina, si es apropiado. still’s diseasekineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of still’s disease, including systemic juvenile idiopathic arthritis (sjia) and adult-onset still’s disease (aosd), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (nsaids) or glucocorticoids. kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (dmards).

멕시코 - 스페인어 - myHealthbox

bayer ag -

스페인 - 스페인어 - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

merck sharp and dohme sp ltd. - ezetimiba, simvastatina - excipientes: - agentes modificadores de los lÍpidos, combinaciones - inhibidores de la hmg-coa reductasa en combinación con otros agentes modificadores de lipidos -

스페인 - 스페인어 - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

organon salud, s.l. - simvastatina; ezetimiba - comprimido - 20 mg/10 mg - simvastatina 20 mg; ezetimiba 10 mg - simvastatina y ezetimiba

스페인 - 스페인어 - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

organon salud, s.l. - simvastatina; ezetimiba - comprimido - 40 mg/10 mg - simvastatina 40 mg; ezetimiba 10 mg - simvastatina y ezetimiba